Kaneka Obtains Positive Results in Preclinical Trials of Drug Eluting Stent.
Tokyo, Japan, June 16, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) ) - Kaneka has obtained positive results from preclinical trials for a drug eluting stent (DES) that it is currently developing.
The Company commissioned Thoraxcenter, a hospital in the Netherlands, to conduct full-scale trials using pigs. The hospital confirmed that Kaneka's DES effectively inhibits blood vessel inflammation and endothelial endothelial /en·do·the·li·al/ (-the´le-al) pertaining to or made up of endothelium.
A layer of cells that lines the inside of certain body cavities, for example, blood vessels. proliferation. Furthermore, the DES helps accelerate the healing of endothelium endothelium /en·do·the·li·um/ (-the´le-um) pl. endothe´lia the layer of epithelial cells that lines the cavities of the heart, the serous cavities, and the lumina of the blood and lymph vessels. . Based on these findings, Kaneka expects that the DES may substantially reduce the risk of stent thrombosis.
Kaneka's DES, which uses cobalt chromium alloy for a stent, consists of tacrolimus, an immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses.
An agent that suppresses the body's immune response. by Astellas Pharma, and biodegradable polymer.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.